Big Data for outcomes and clinical research:

major advance or improvement needed

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Creation of Big Data repositories is now emphasized at virtually all research institutions and the NIH, but the number of publications describing patient outcomes from these sources appears modest.1 Why is this so; what factors limit what should be a hugely productive resource, and how can we improve the impact of this use of Big Data? Why does this issue require greater physician engagement and understanding to solve? The integration of clinical, laboratory, and financial data is required to describe disease and treatment outcomes as well as treatment value.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Roy B. Jones
Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX
Amar Chahal
Chief operating officer, Velos Inc.
Dianne Reeves, MD
Retired associate director, Center for Biomedical Informatics and Information Technology, NCI
Gregory H. Jones
Resident, University of Texas School of Medicine
Charles S. Martinez
Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX
Table of Contents

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

The Cancer Letter staff were finalists for nine 2025 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists—seven for journalism; two for design—and won first place for four. The Cancer Letter’s entries recognized by SPJ include investigative journalism, series, breaking news, features, photojournalism, commentary, illustration, and front page design. This is...

Roy B. Jones
Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX
Amar Chahal
Chief operating officer, Velos Inc.
Dianne Reeves, MD
Retired associate director, Center for Biomedical Informatics and Information Technology, NCI
Gregory H. Jones
Resident, University of Texas School of Medicine
Charles S. Martinez
Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login